Skip to content

Inhibrx Biosciences, Inc. INBX Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$130.19M+7.0%-$140.06M-30.6%-$107.22M+7.4%-$115.83M-107%$1.77B+2.0%
$2.35M-5.6%$2.48M-4.8%$2.61M-6.4%$2.79M+7.2%$2.6M+13.8%
$11.34M+1.8%$11.14M-2.1%$11.38M+1.9%$11.17M-79.5%$54.57M-6.7%
-$131.93M-1.6%-$129.79M+9.5%-$143.39M-2.5%-$139.85M+16.4%-$167.25M+14.0%
$1.5M-42.3%
-$1.5M+42.3%
$77.07M-24.0%$101.45M
-$35.96M+71.3%
-$131.94M-1.6%-$129.83M+9.5%-$143.44M-2.4%-$140.13M+17.0%-$168.75M+14.3%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Inhibrx Biosciences, Inc. generate?
Inhibrx Biosciences, Inc. (INBX) generated -$131.9M in operating cash flow over the trailing twelve months.
What is Inhibrx Biosciences, Inc.'s free cash flow?
After $47.0K of capital expenditures, Inhibrx Biosciences, Inc.'s free cash flow was -$131.9M over the trailing twelve months, up 21.8% year over year.
Where does Inhibrx Biosciences, Inc.'s cash flow data come from?
Every line is extracted from Inhibrx Biosciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.